复发制药公司获得FDA批准用于研究癌症药物REC-1245. Recursion Pharmaceuticals receives FDA clearance for investigational cancer drug REC-1245.

复发制药公司已获得FDA批准, 针对REC-1245的新药申请进行研究. Recursion Pharmaceuticals has received FDA clearance for its Investigational New Drug Application for REC-1245. 这种药物是一种潜在的一流的BM39降解器,旨在治疗生物标记富含固体肿瘤和淋巴瘤。 This drug is a potential first-in-class RBM39 degrader aimed at treating biomarker-enriched solid tumors and lymphoma. 这一发展是癌症治疗选择方案向前迈出的重要一步。 This development represents a significant step forward in cancer treatment options.